Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach

2 Apr 2014

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Drug Transport and Resistance Mechanisms
Share to Pharmacogenetics and Drug Metabolism

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 24704000
DOI: 10.1016/j.gene.2014.04.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approachPMID 24704000Read ↗

Pharmacogenomics of breast cancer therapy: An updateSemantic proximity Read ↗

[Novel target therapies used in breast cancer management].Semantic proximity Read ↗

Optimizing chemotherapy regimens for patients with early-stage breast cancer.Semantic proximity Read ↗

Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designsSemantic proximity Read ↗

Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer.Semantic proximity Read ↗

Evaluation of drug-specific multigene markers to predict aromatase inhibitor efficacy in advanced breast cancer: a cohort study from Danish Breast Cancer Cooperative GroupSemantic proximity Read ↗

Prognostic molecular markers and neoadjuvant therapy response in anthracycline-treated breast cancer patientsSemantic proximity Read ↗

Understanding tumour growth variability in patient-derived breast cancer xenograft models identifies early responders and biomarkers of resistance to PARP inhibitionSemantic proximity Read ↗

Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review.Semantic proximity Read ↗

Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials.Semantic proximity Read ↗

Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.Semantic proximity Read ↗

[Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.